Loading clinical trials...

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia | Clinical Trials | Clareo Health

COMPLETED

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

An Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia Who Have a History of Suboptimal Adherence and Are Currently on Treatment With Oral Aripiprazole

NCT02050854•Otsuka Pharmaceutical Development & Commercialization, Inc.

View on ClinicalTrials.gov

Summary

Detailed Description

The purpose of this study is to evaluate the pharmacokinetics of aripiprazole in subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal aderence and are currently on treatment with oral aripiprazole. This will be an open-label observational pilot trial to compare the PK profile of aripiprazole at Visit 1 of subjects who are receiving oral aripiprazole and who have the potential for suboptimal adherent behavior with their assigned medication. Information obtained in the current trial will be used to inform the conduct of a randomized, open-label, parallel-group trial to assess between-group change from baseline adherence using PK sampling in subjects receiving oral aripiprazole with or without the MIND1 System (Protocol 316-13-211).

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male and female subjects 18 to 55 years of age (inclusive) at time of informed consent
•Subjects with a primary current Axis 1 disorder of bipolar 1 disorder or schizophrenia as defined by DSM-IV-TR criteria, who have been treated in the outpatient setting for at least 2 months before screening
•Subjects with a score of 1-7 on the Morisky 8-Item Medication Adherence Scale (MMAS-8)
•Subjects with bipolar 1 disorder who have a YMRS score of 10 to 25 (inclusive), or subjects with schizophrenia who have a PANSS score of 60 to 90 (inclusive)
•Subjects able to ingest oral medication
•Subjects currently prescribed oral aripiprazole for either bipolar 1 disorder or schizophrenia, and who have not had any changes in their Aripiprazole regimen or dose over the last 2 weeks
•Subjects who have an exacerbation of mood or psychotic symptoms when they are not receiving treatment or are noncompliant with treatment for their bipolar 1 disorder or schizophrenia
•For subjects enrolled with bipolar 1 disorder, the current bipolar episode is mixed or manic (the current must not be a depressive episode)

Exclusion Criteria

•Subjects with a current Axis I (DSM-IV-TR) diagnosis other than bipolar 1 disorder or schizophrenia
•Subjects with a current Axis II (DSM-IV-TR) diagnosis
•Subjects not able to self-administer their medication
•Subjects who reside in or attend a facility where medication is administered to them
•Subjects who have a score of 0 or 8 on the Morisky 8-Item Medication Adherence Scale (MMAS-8)
•Subjects who currently meet DSM-IV-TR criteria for substance dependence
•Subjects with a history of inpatient hospitalization for any psychiatric reason within the past 2 months before screening
•Subjects who have received any investigational product within the last 30 days
•Subjects known to be allergic, intolerant, or unresponsive to prior treatment with Aripiprazole or other quinolinones
•Subjects who, per investigator's judgment, are acutely psychotic or manic and/or exhibit symptoms currently requiring hospitalization

Locations (5)

Garden Grove, California, United States

Atlanta, Georgia, United States

Decatur, Georgia, United States

Rockville, Maryland, United States

Bellevue, Washington, United States

Key Dates

Start Date

December 1, 2013

Primary Completion Date

January 1, 2014

Completion Date

January 1, 2014

Last Updated

January 31, 2014

Enrollment

ACTUAL participants

Conditions

Bipolar 1 DisorderSchizophreniaMental DisorderNervous System Disorders

Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders

NCT01778504

Neuropsychiatric DisorderNeurological Disorder+2 more

View study

RECRUITING

Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal

NCT06690151

Heart Disease CongenitalNeurodevelopmental Disorder

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 31, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

Inclusion Criteria

Exclusion Criteria

Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders

Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal

Psychiatric Multi-omics and Neuroimaging Project

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services